Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

8.29
-0.5150-5.85%
Post-market: 8.290.00000.00%17:36 EDT
Volume:9.00M
Turnover:73.92M
Market Cap:2.12B
PE:-5.51
High:8.46
Open:8.34
Low:8.05
Close:8.81
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:2.10
T/O Rate:4.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-4.66
PE(LYR):6.85

Loading ...

Kioxia Ships Next-gen Memory Samples as AI Boom Fuels Dramatic Comeback

Reuters
·
Jul 03

Biocryst Grants New Hires Stock Options for 33,950 Shares at $9.65 Each

Reuters
·
Jul 02

Biocryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

TIPRANKS
·
Jun 30

Biocryst Pharmaceuticals is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jun 30

Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
Jun 30

BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End

MT Newswires Live
·
Jun 29

Biocryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Reaffirms Full Year 2026 Orladeyo and Total Company Revenue Guidance

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Shifts Strategic Focus to External Innovation for Rare Disease Pipeline

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - to Make Orladeyo Oral Pellets Available in Early August 2026

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - to Close Birmingham Discovery Center and End Internal Discovery Programs by End 2026

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Completes Enrollment in Phase 3 Alpha-orbit Study for Navenibart

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Improves 2026 Non-gaap Operating Expense Guidance to $420-$440 Mln

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals Inc Fy2026 REV View $667.5 Mln

THOMSON REUTERS
·
Jun 29

How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups

Simply Wall St.
·
Jun 15

BioCryst shareholders approve amended stock incentive plan, add 7 million shares

Reuters
·
Jun 13

BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment

MT Newswires Live
·
Jun 12

BioCryst says post hoc ALPHA-STAR analysis shows navenibart cuts HAE attack rates across patient subgroups

Reuters
·
Jun 12

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of Hae Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 12